Pidilizumab
http://dbpedia.org/resource/Pidilizumab an entity of type: Thing
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
rdf:langString
rdf:langString
Pidilizumab
xsd:integer
36964640
xsd:integer
984406447
rdf:langString
none
xsd:integer
6424
xsd:integer
1036730
rdf:langString
none
xsd:integer
9920
rdf:langString
D10390
xsd:integer
1704
xsd:integer
2002
xsd:integer
48
rdf:langString
zu/o
rdf:langString
mab
rdf:langString
B932PAQ1BQ
rdf:langString
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
rdf:langString
mab
xsd:nonNegativeInteger
3780
xsd:string
1036730-42-3
xsd:string
B932PAQ1BQ
xsd:string
D10390